The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

25 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).EBI
Ontario Institute For Cancer Research
Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.EBI
University of Michigan
SAH derived potent and selective EZH2 inhibitors.EBI
Pfizer
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.EBI
University of North Carolina At Chapel Hill
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.EBI
Chinese Academy of Sciences
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.EBI
TBA
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.EBI
University of California San Francisco
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.EBI
Sun Yat-Sen University
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.EBI
Sun Yat-Sen University
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.EBI
Shanghai Jiao Tong University
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs).EBI
Shanghai Jiao Tong University
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.EBI
Sun Yat-Sen University
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective.EBI
China Pharmaceutical University
Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation.EBI
University of Virginia
Discovery of EBI
China Pharmaceutical University
Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.EBI
China Pharmaceutical University
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.EBI
Chinese Academy of Sciences
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.EBI
China Pharmaceutical University
Engineering Fluorine into Verticillins (Epipolythiodioxopiperazine Alkaloids) via Precursor-Directed Biosynthesis.EBI
University of North Carolina At Greensboro
Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.EBI
China Pharmaceutical University
Methyllysine binding domains: Structural insight and small molecule probe development.EBI
University of Connecticut
Bicyclic DGK InhibitorsBDB
Incyte
CARM1 INHIBITORS AND USES THEREOFBDB
Epizyme
Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereofBDB
280 Bio
Morpholine derivativeBDB
Hoffmann-La Roche